Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Reconciliation of Consolidated Operating Expenses and Loss

A reconciliation to consolidated operating expenses as our single segment operating loss for the twelve months ended December 31, 2024 and 2023 is included in the table below:

	Year Ended December 31,
	2024		2023
Direct research and development expenses
Research and development salaries and benefits	$	8,048,062	$	5,193,554
Clinical trial expense		4,169,487		809,678
Lab supplies and animal care		2,737,075		2,740,835
Lab services, consulting, and other direct research costs		7,295,739		1,471,879
Contract Manufacturing		—		386,983
Total direct research and development expenses		22,250,363		10,602,929
Indirect research and development expenses		6,694,046		5,292,590
Share based compensation (research and development)		1,307,258		619,486
Total research and development expense		30,251,667		16,515,005
General and administrative expense
Administrative payroll		6,563,608		6,614,660
Professional fees and travel		1,515,131		10,647,419
Insurance, office expense, and other administrative expenses		4,267,987		4,732,994
Share based compensation (general and administrative)		1,634,537		1,804,233
Total general and administrative expenses		13,981,263		23,799,306
Total operating expense	$	44,232,930	$	40,314,311